CONMED Exits Gastroenterology Business, Plans to Use Proceeds for Strategic Investments and Debt Paydown

CONMED Corporation plans to exit its gastroenterology product lines, focusing on core markets like minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. The move is expected to generate $90-95 million in revenue in 2025 and improve gross margin profile by 80 basis points. CONMED will use proceeds from the Gore agreement for general corporate purposes, including strategic investments, debt paydown, and share repurchases. The company does not expect a material impact on 2025 financial results and plans to provide full 2026 guidance on its Q4 2025 earnings call.